Thomas H. Lee, M.D., and Alice H. Chen, M.D., M.P.H.
doi : 10.1056/NEJMp2100574
N Engl J Med 2021; 384:685-687
Ateev Mehrotra, M.D., Alok Nimgaonkar, B.A., and Barak Richman, J.D., Ph.D.
doi : 10.1056/NEJMp2031608
N Engl J Med 2021; 384:687-690
Simone Vais, M.D.
doi : 10.1056/NEJMp2029725
N Engl J Med 2021; 384:690-691
The RECOVERY Collaborative Group*
doi : 10.1056/NEJMoa2021436
N Engl J Med 2021; 384:693-704
Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.
Nikhil C. Munshi, M.D., Larry D. Anderson, Jr., M.D., Ph.D., Nina Shah, M.D., Deepu Madduri, M.D., Jes?s Berdeja, M.D., Sagar Lonial, M.D., Noopur Raje, M.D., Yi Lin, M.D., Ph.D., David Siegel, M.D., Ph.D., Albert Oriol, M.D., Philippe Moreau, M.D., Ibrahim Yakoub-Agha, M.D., Ph.D., Michel Delforge, M.D., Michele Cavo, M.D., Hermann Einsele, M.D., Hartmut Goldschmidt, M.D., Katja Weisel, M.D., Alessandro Rambaldi, M.D., Donna Reece, M.D., Fabio Petrocca, M.D., Monica Massaro, M.P.H., Jamie N. Connarn, Ph.D., Shari Kaiser, Ph.D., Payal Patel, Ph.D., Liping Huang, Ph.D., Timothy B. Campbell, M.D., Ph.D., Kristen Hege, M.D., and Jes?s San-Miguel, M.D., Ph.D.
doi : 10.1056/NEJMoa2024850
N Engl J Med 2021; 384:705-716
Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma.
Stephen K. Brannan, M.D., Sharon Sawchak, R.N., Andrew C. Miller, Ph.D., Jeffrey A. Lieberman, M.D., Steven M. Paul, M.D., and Alan Breier, M.D.
doi : 10.1056/NEJMoa2017015
N Engl J Med 2021; 384:717-726
The muscarinic receptor agonist xanomeline has antipsychotic properties and is devoid of dopamine receptor–blocking activity but causes cholinergic adverse events. Trospium is a peripherally restricted muscarinic receptor antagonist that reduces peripheral cholinergic effects of xanomeline. The efficacy and safety of combined xanomeline and trospium in patients with schizophrenia are unknown.
Ali T. Taher, M.D., Ph.D., Khaled M. Musallam, M.D., Ph.D., and M. Domenica Cappellini, M.D.
doi : 10.1056/NEJMra2021838
N Engl J Med 2021; 384:727-743
Bina S. Menon, M.R.C.P., and Kok-Hoi Teh, M.R.C.P.C.H.
doi : 10.1056/NEJMicm2026082
N Engl J Med 2021; 384:744
Shu Hui Neo, M.B., B.S., and Lui Shiong Lee, M.B., B.S.
doi : 10.1056/NEJMicm2026560
N Engl J Med 2021; 384:e24
Marc A. Bouffard, M.D., Bart K. Chwalisz, M.D., Javier M. Romero, M.D., Isabel C. Arrillaga-Romany, M.D., and Lucas R. Massoth, M.D.
doi : 10.1056/NEJMcpc2027089
N Engl J Med 2021; 384:745-753
H. Clifford Lane, M.D., and Anthony S. Fauci, M.D.
doi : 10.1056/NEJMe2024638
N Engl J Med 2021; 384:755-757
Sharon-Lise T. Normand, Ph.D.
doi : 10.1056/NEJMe2025674
N Engl J Med 2021; 384:757-758
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2103272
N Engl J Med 2021; 384:e40
Brad Smith, M.Phil.
doi : 10.1056/NEJMsb2031138
N Engl J Med 2021; 384:759-764
Philip Van Damme, M.D., Ph.D., and Wim Robberecht, M.D., Ph.D.
doi : 10.1056/NEJMcibr2031048
N Engl J Med 2021; 384:765-767
Zinzi D. Bailey, Sc.D., M.S.P.H., Justin M. Feldman, Sc.D., and Mary T. Bassett, M.D., M.P.H.
doi : 10.1056/NEJMms2025396
N Engl J Med 2021; 384:768-773
doi : 10.1056/NEJMc2032052
N Engl J Med 2021; 384:774-775
doi : 10.1056/NEJMc2034992
N Engl J Med 2021; 384:776-779
doi : 10.1056/NEJMc2035798
N Engl J Med 2021; 384:e26
doi : 10.1056/NEJMx210001
N Engl J Med 2021; 384:782
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟